A Cancer-Heart Disease Link

Mutations known to increase the risk of developing ovarian and breast cancer may also make carriers susceptible to heart failure.

Written byCristina Luiggi
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

WELLCOME IMAGES, ANNIE CAVANAGH

Carriers of BRCA1 and BRCA2 mutations may also be at an increased risk of developing heart failure, two new studies published in Nature Communications and The Journal of Biological Chemistry suggest. The researchers found that both mice and humans with oncogenic mutations in the genes suffered much more extensive damage in cardiac tissue after a heart attack—presumably due to increased apoptosis in cardiomyocytes and an inability to repair double-strand breaks in DNA. As a result, mice with BRCA1 and BRCA2 mutations were four to five times more likely to die following a heart attack.

In addition, BRCA1 and BRCA2-mutated mice that were treated with doxorubicin—a chemotherapeutic agent commonly used for the treatment of a variety of cancers including breast and ovarian—were also at a two-fold ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies